NeuraLight launched a prospective cross-sectional trial to examine how oculometric measures correlate with standard clinical assessments in idiopathic Parkinson’s disease.
Registered as NCT05437003 on ClinicalTrials.gov, the study is carried out at Rabin Medical Center under the leadership of Prof. Ruth Djaldetti, a leading movement disorders specialist, and with Dr. Jonathan Reiner as a principal investigator.
By assessing the correlations between eye-movement metrics and clinical severity, the study aims to validate oculometric biomarkers as objective, sensitive indicators that complement traditional neurological evaluations in PD.
This work represents another step in NeuraLight’s mission to transform neurology and care through precise, AI-driven biomarkers.